ProCE Banner Activity

CME

Evolving Treatment Paradigms for Gynecologic Malignancies: Application for Current and Future Practice

Multimedia
In this on-demand webcast from a live symposium, oncology experts David Scott Miller, MD, FACOG, FACS; Nicoletta Colombo, MD; and Shannon N. Westin, MD, MPH, discuss the latest data on managing patients with cervical, endometrial, and ovarian cancers.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 07, 2022

Expiration: June 06, 2023

No longer available for credit.

Share

Faculty

Nicoletta Colombo

Nicoletta Colombo, MD, PhD

Associate Professor of Obsterics and Gynecology
European Institute of Oncology 
University of Milan-Bicocca
Milan, Italy  

Lesley Scott

Lesley Scott

Shannon N. Westin

Shannon N. Westin, MD, MPH

Associate Professor
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Eisai Inc.

GlaxoSmithKline

ImmunoGen, Inc.

Merck Sharp & Dohme Corp.

Target Audience

This educational program is intended for medical oncologists and other healthcare professionals who treat patients with gynecologic cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Assess appropriate predictive biomarkers in gynecologic cancers to guide treatment selection and clinical trial eligibility
  • Evaluate available practice-changing clinical data on new targeted therapies as single-agent or combination therapies in cervical, endometrial, and ovarian cancers
  • Plan treatment strategies for patients with cervical, endometrial, and ovarian cancers that incorporate novel therapies and combination strategies
  • Select maintenance therapy for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings
  • Describe the role of ICI-based therapy in endometrial cancer classified as microsatellite stable

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Nicoletta Colombo, MD, PhD

Associate Professor of Obsterics and Gynecology
European Institute of Oncology 
University of Milan-Bicocca
Milan, Italy  

Nicoletta Colombo, MD, has disclosed that she has received consulting fees from AstraZeneca, Clovis, Eisai, GlaxoSmithKline, ImmunoGen, Mersana, MSD, Pfizer, and Roche.

Lesley Scott,

David Scott Miller, MD, FACOG, FACS, has disclosed that he has received funds for research support from EMD Serono; consulting fees from AbbVie, Agenus, Alexion Pharmaceuticals, AstraZeneca, Asymmetric Therapeutics, Boston Biomedical Research Institute, Clovis Oncology, Eisai, Eisai Europe, EMD Serono, Genentech, GlaxoSmithKline, Guardant Health, Immunogen, Incyte, iTeso Belgium, Janssen Oncology, Karyopharm Therapeutics, Merck Sharp & Dohme, Myriad Genetic Laboratories, Novocure, Seagen, Tarveda Therapeutics, and Tesaro; and research funds paid to his institution from Advaxis, Advenchen, Aeterna Zentaris, Agenus, Akesobio, Aprea AB, AstraZeneca, Immunogen, Incyte, Janssen, Karyopharm Therapeutics, Leap Therapeutics, Mateon Therapeutics, Merck Sharp & Dohme, Millennium Pharmaceuticals, Novartis, NVision, Regeneron, Syros Pharmaceuticals, Tesaro, TRACON Pharma, US Biotest, and Xenetic Biosciences.

Shannon N. Westin, MD, MPH

Associate Professor
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Shannon N. Westin, MD, MPH, has disclosed that she has received funds for research support from AstraZeneca, Bayer, Clovis Oncology, Cotinga, GlaxoSmithKline, Mereo, Novartis, OncXerna, Roche/Genentech, and Zentalis and consulting fees from Agenus, AstraZeneca, Caris, Clovis Oncology, Eisai, EQRX, GlaxoSmithKline, ImmunoGen, Karyopharm, Lilly, Merck, Mereo, Mersana, Roche/Genentech, Vincerx, and Zentalis.

Staff Disclosure

Staff

Jerfiz Constanzo, PhD, MBA

Scientific Director

Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 07, 2022, through June 06, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, and competence of learners in selecting individualized treatment regimens for patients with gynecologic malignancies.